• Latest Posts

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis invests in Irish Upstart tackling Chronic Inflammation

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

Novartis delivers German Biotech’s 12th Antibody to Clinics

ADVERTISEMENT

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

Cancer: World Best Ever CAR-T Results have Just been Disclosed

The European Union Finances the Future of CAR-T Manufacturing

World CAR-T Leader Starts New Program with a UK Biotech

World’s First Microbiome Fund Swells to €160M With Major Pharma Also Chipping In

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

ADVERTISEMENT